LBS 008

Drug Profile

LBS 008

Alternative Names: LBS008

Latest Information Update: 13 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Columbia University
  • Developer Columbia University; Lin Bioscience
  • Class Eye disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Dry age-related macular degeneration; Stargardt disease

Most Recent Events

  • 07 Jan 2017 Lin Bioscience in collaboration with Columbia University and the National Institute of Health plans a phase I trial for Dry age-related macular degeneration and Stargardt macular dystrophy 1 in USA
  • 06 Jan 2017 Preclinical trials in Dry age-related macular degeneration in USA prior to January 2017 (PO)
  • 06 Jan 2017 Preclinical trials in Stargardt disease 1 in USA prior to January 2017 (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top